LYNNETTE AVERILL to Antidepressive Agents
This is a "connection" page, showing publications LYNNETTE AVERILL has written about Antidepressive Agents.
Connection Strength
0.915
-
mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression. J Affect Disord. 2022 04 15; 303:91-97.
Score: 0.164
-
Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence. Adv Pharmacol. 2020; 89:163-194.
Score: 0.146
-
The Neurobiology and Pharmacotherapy of Posttraumatic Stress Disorder. Annu Rev Pharmacol Toxicol. 2019 01 06; 59:171-189.
Score: 0.130
-
The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology. 2018 09; 43(10):2154-2160.
Score: 0.128
-
Ketamine Treatment and Global Brain Connectivity in Major Depression. Neuropsychopharmacology. 2017 May; 42(6):1210-1219.
Score: 0.113
-
Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial. Neuropsychopharmacology. 2023 10; 48(11):1586-1593.
Score: 0.045
-
Replication of distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2023 01 15; 321:140-146.
Score: 0.043
-
Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology. 2022 07; 47(8):1574-1581.
Score: 0.041
-
A robust and reproducible connectome fingerprint of ketamine is highly associated with the connectomic signature of antidepressants. Neuropsychopharmacology. 2021 01; 46(2):478-485.
Score: 0.037
-
Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. Neuropsychopharmacology. 2020 05; 45(6):990-997.
Score: 0.036
-
Repeated ketamine infusions for antidepressant-resistant PTSD: Methods of a multicenter, randomized, placebo-controlled clinical trial. Contemp Clin Trials. 2019 06; 81:11-18.
Score: 0.034